Endpoints NewsOriginal article
Agios’ second shot at sickle cell disease falls short
Phase 2negativetebapivatNegative
AI Analysis
Summary
Agios Pharmaceuticals is discontinuing tebapivat, its second-generation sickle cell disease candidate, following disappointing results from a Phase 2 trial. The drug represented the company's primary opportunity in the sickle cell space.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
lackluster results from mid-stage trial
Importance:7/10
Sentiment:
-0.80
sickle cell diseasedrug discontinuationPhase 2 failurepipeline reduction
Related Companies
Read the original article
Published by Endpoints News on July 21, 2026 3:14 PM